Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
09:17pm, Thursday, 04'th May 2023
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to earnings of $3.85 per share a year ago.
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
01:40pm, Wednesday, 05'th Apr 2023
While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts
Is the Options Market Predicting a Spike in Vir Biotechnology (VIR) Stock?
09:59am, Wednesday, 29'th Mar 2023
Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
04:05pm, Wednesday, 08'th Mar 2023
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of
The Top 7 Growth Stocks in Biotech
06:57pm, Friday, 03'rd Mar 2023
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Thursday, 23'rd Feb 2023
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -1,800% and 80.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st
This biotech stock could double from here: Goldman Sachs
02:02pm, Tuesday, 21'st Feb 2023
Vir Biotechnology Inc (NASDAQ: VIR) jumped nearly 10% this morning after a Goldman Sachs analyst turned super bullish on the clinical-stage immunology company.
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
02:19pm, Thursday, 02'nd Feb 2023
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edg
GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook
12:02pm, Wednesday, 01'st Feb 2023
GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.
Vir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgrade
01:33pm, Tuesday, 24'th Jan 2023
Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 Stocks That Could Turn $100 Into $1,000 by 2028
07:15am, Sunday, 22'nd Jan 2023
These growth stocks have substantial tailwinds.
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
11:17am, Friday, 20'th Jan 2023
Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.
Vir Biotechnology: High Potential Returns With High Volatility Risks
02:59am, Thursday, 19'th Jan 2023
Vir Biotechnology is a commercial-stage immunology company that bases its activity on infectious disease prevention. The agreement with GSK made it possible to obtain large revenues and profits in 202
Vir Biotechnology: The First Entry In My Long Term Value Portfolio
03:25am, Sunday, 08'th Jan 2023
Today, I explain why I've taken a position in VIR, including going over its pipeline, partners, and anticipated milestones. I then look at the company's valuation and cash position as well as Seeking
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
11:36am, Wednesday, 28'th Dec 2022
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
